A phase Ib study of everolimus combined with metformin for patients with advanced cancer

Background The efficacy to monotherapy with the mTOR inhibitor everolimus in advanced cancer is often limited due to therapy resistance. Combining everolimus with metformin may decrease the chance of therapy resistance. Methods Patients received everolimus and metformin in a 3 + 3 dose-escalation sc...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Invest New Drugs
Asıl Yazarlar: Molenaar, Remco J., van de Venne, Tim, Weterman, Mariëtte J., Mathot, Ron A., Klümpen, Heinz-Josef, Richel, Dick J., Wilmink, Johanna W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer US 2017
Konular:
Phase I Studies
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805805/
https://ncbi.nlm.nih.gov/pubmed/28616837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0478-4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller